Non-Invasive Womb Cancer Test for Postmenopausal Bleeding 2026

Womb cancer diagnosis may soon become far less invasive thanks to a new test developed by UK doctors. The simple test, which analyzes cells from urine and vaginal fluid, could help rule out womb cancer in women who experience bleeding after menopause. This breakthrough has the potential to transform care for thousands of women each year and spare them from uncomfortable and costly procedures.

Why a Non-Invasive Test for Womb Cancer Matters

Every year, hundreds of thousands of women worldwide are diagnosed with womb cancer. Postmenopausal bleeding triggers an urgent cancer referral, but only about 5% to 10% of women who report bleeding actually have an underlying cancer. Currently, diagnostic tests for womb cancer—including internal ultrasound scans, biopsies of the womb lining, and hysteroscopy (where a camera is passed into the womb)—are all invasive, uncomfortable, and expensive for healthcare systems.

How the New Test Works

Developed at the University of Manchester and Manchester University NHS Foundation Trust, the new test examines cells collected from a simple urine sample and a vaginal fluid sample. It is cheap, non-invasive, and could be performed in an outpatient setting. In a study assessing the test, 1,864 women attending seven hospitals in north-west England with postmenopausal bleeding provided samples before their routine tests. Of these women, 5% (99 of the 1,864) were diagnosed with womb cancer via biopsy or surgery.

Using the new test, cytologists who were unaware of the women's diagnoses identified 80 of the 99 womb cancers and correctly returned a negative result for 93% of women who did not have womb cancer. This high accuracy suggests the test could be used as a triage tool, reducing the need for invasive procedures in the majority of women who do not have cancer.

Comparison of Diagnostic Methods for Womb Cancer

Key Takeaways

• The new test is non-invasive, using urine and vaginal fluid samples.
• It correctly identified 80 out of 99 womb cancers in a study of 1,864 women.
• It returned a negative result for 93% of women without cancer.
• If implemented, it could spare thousands of women from invasive procedures.
• It is also cost-effective for healthcare systems.

Frequently Asked Questions

This development marks a significant step forward in women's health, offering a simpler, kinder, and more cost-effective way to diagnose womb cancer. Further research and clinical trials will determine how quickly this test can be rolled out across healthcare systems.

Best Products We’ve Tested and Rated

Our testing team has hands-on reviews of grips, golf simulator under, electric cart hills, turf simulator, and outdoor mats. Every option below was compared across price, build quality, and real-world performance, with honest pros and cons. We update these guides regularly as new models arrive, so the recommendations stay current.

Our testing team has hands-on reviews of balls, hitting mats, bag mgi zip navigator, bags walking push carts, and hitting strips. Every option below was compared across price, build quality, and real-world performance, with honest pros and cons. We update these guides regularly as new models arrive, so the recommendations stay current.